Figure 2 | Scientific Reports

Figure 2

From: Mass COVID-19 patient screening using UvsX and UvsY mediated DNA recombination and high throughput parallel sequencing

Figure 2

REMBRANDT can identify SARS-CoV-2 positive patient samples from raw and extracted patient samples. (A) Patient information from tested individuals including age, gender, days of test following symptoms and COVID and RNaseP Ct values from CDC COVID assay. (B) Number of SARS-CoV-2 reads mapped to negative control (-ve control), negative patients (-ve patient samples) and SARS-CoV-2 positive patients (+ve patients) from raw samples. Graph generated using Prism v: 9.2.0 (Home-GraphPad). (C) Number of SARS-CoV-2 reads mapped to negative control (-ve control), negative patients (-ve patient samples) and SARS-CoV-2 positive patients (+ve patients) from RNA extracted samples. Graph generated using Prism v: 9.2.0 (Home-GraphPad). (D) Comparison of the number of SARS-CoV-2 reads from each patient comparing raw and extracted patient samples. Graph generated using Prism v: 9.2.0 (Home-GraphPad). (E) Schematic detailing the REMBRANDT pipeline for testing for COVID-19. Image generated using Biorender (BioRender).

Back to article page